Form 4: Stoke Therapeutics Interim CEO Ian F. Smith Acquires Stock Options
SEC Form 4 Filing
Ian F. Smith, Interim CEO of Stoke Therapeutics, acquired stock options for 238,420 shares of common stock on March 20, 2025.
Summary
- On March 20, 2025, Ian F. Smith, the Interim CEO of Stoke Therapeutics, acquired stock options to purchase 238,420 shares of the company's common stock.
- The exercise price of these options is $8.33 per share.
- The options vest ratably over 12 months from the grant date, contingent upon Smith's continued service to Stoke Therapeutics.
- The options expire on March 19, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.
Positives
- The acquisition of stock options by the Interim CEO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes continued service to the company.
Industry Context
This is a standard practice for incentivizing executives in publicly traded companies, aligning their interests with shareholder value.
Comparison to Industry Standards
- Stock option grants are a common form of executive compensation in the biotechnology industry.
- Companies like BioMarin Pharmaceutical and Sarepta Therapeutics also use stock options to incentivize their leadership teams.
- The vesting schedule and exercise price are typical for such grants, designed to reward long-term performance.
Stakeholder Impact
- Shareholders may view this positively as it incentivizes the CEO to improve company performance.
- Employees may see this as a sign of stability and commitment from the leadership.
Key Dates
| Date | Description |
|---|---|
| 03/20/2025 | Date of the transaction: Ian F. Smith acquired stock options. |
| 03/20/2025 | Options vest ratably as to 1/12 of the total award on the monthly anniversary of the grant date. |
| 03/19/2035 | Expiration date of the stock options. |
Keywords
Stock Options, Form 4, Insider Trading, Stoke Therapeutics, Ian F. Smith, STOK, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.